Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinhuaijiaonang is a traditional Chinese medicine (TCM) capsule developed by Jilin Tianheng Pharmaceutical for the treatment of gout and hyperuricemia. It is specifically indicated for patients presenting with the "damp-heat accumulation" (湿热蕴结) syndrome pattern according to TCM diagnostic criteria. The formulation is currently undergoing Phase II clinical evaluation in China (CTR20243105) to assess its efficacy and safety in reducing serum uric acid levels and managing gout symptoms in adults. As a botanical-based therapy, its therapeutic profile likely involves anti-inflammatory activity and the regulation of urate metabolism, though its specific molecular targets are characteristic of multi-component herbal formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qinhuaijiaonang.